Filing Flows › Aquestive Therapeutics (AQST) › Q1 2025
Aquestive Therapeutics (AQST) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Aquestive Therapeutics (AQST) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), -28% from a year earlier and -27% from the quarter before. Operating margin was -222.1%, net loss $22.9M (263.0% of revenue).
Aquestive Therapeutics, Q1 2025: revenue $8.7M (-28% year over year), operating margin -222.1%, net loss $22.9M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.7M | -27% | -28% |
| Operating profit | −$19.4M | — | — |
| Net earnings | −$22.9M | — | — |
| Operating cash flow | −$23.4M | — | — |
What changed
Revenue was $8.7M in Q1 2025, down 28% year over year and down 27% from the previous quarter. Manufacture and supply revenue was the largest line at 82% of revenue. Manufacture and supply revenue lost $3.3M year over year (down 32%), 100% of the total change.
Operating costs exceeded revenue by $19.4M, an operating margin of -222.1%. Total costs grew 34% against a revenue fall of 28%. The fastest-growing cost line was SG&A (+78%). The quarter ended with a net loss of $22.9M, wider than the previous quarter's $17.1M loss.
Operating cash flow was −$23.4M. Non-cash charges added back $139K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $2.2M. Capital expenditures of $135K exceeded it, leaving free cash flow of −$23.5M.
Questions
What was Aquestive Therapeutics' revenue in the first quarter 2025?
Aquestive Therapeutics (AQST) reported revenue of $8.7M for the first quarter 2025 (Q1 2025), -28% from a year earlier and -27% from the quarter before.
Was Aquestive Therapeutics profitable in the first quarter 2025?
Operating loss was $19.4M (-222.1% of revenue) and net loss $22.9M.